Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Travere Therapeutics, Inc. (RTRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Travere Therapeutics Reports Second Quarter 2023 Financial Results"
05/04/2023 8-K Quarterly results
Docs: "Travere Therapeutics Reports First Quarter 2023 Financial Results FILSPARI™ granted accelerated approval by FDA for the reduction of proteinuria in IgA nephropathy on February 17th, 2023&#59; commercial launch underway"
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
10/28/2021 8-K Quarterly results
Docs: "Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Progress"
07/29/2021 8-K Quarterly results
Docs: "Travere Therapeutics Reports Second Quarter 2021 Financial Results"
05/06/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Retrophin Reports Third Quarter 2020 Financial Results"
07/30/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
02/24/2020 8-K Quarterly results
10/30/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Retrophin Reports First Quarter 2019 Financial Results Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued quarter over quarter growth in net product sales SAN DIEGO, May 7, 2019 -"
02/26/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Retrophin Reports Third Quarter 2018 Financial Results Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 SAN DIEGO, November 1, 2018 -"
07/26/2018 8-K Quarterly results
Docs: "Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; top-line results expected in early 2019 Retrophin Chief Executive Officer Stephen Aselage announces his decision to retire; Board of Directors initiates search for successor SAN DIEGO, July 26, 2018 -"
05/01/2018 8-K Quarterly results
Docs: "Retrophin Reports First Quarter 2018 Financial Results Company obtains FDA and EMA feedback on pathway to NDA and MAA filing for sparsentan in IgA nephropathy; single Phase 3 trial expected to initiate in the fourth quarter of 2018 Pivotal Phase 3 DUPLEX Study of sparsentan in FSGS underway to support Subpart H NDA filing Revenue rose 14 percent to $38 million during the first quarter of 2018"
02/27/2018 8-K Quarterly results
Docs: "Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018 Clinical development of sparsentan in IgAN and CNSA-001 in PKU expected to initiate in 2018 Revenue increased 16 percent to $155 million during 2017 SAN DIEGO -"
11/07/2017 8-K Quarterly results
Docs: "Retrophin Reports Third Quarter 2017 Financial Results Phase 3 FORT Study of fosmetpantotenate continues to enroll PKAN patients Third quarter revenues increased 19 percent to $40 million"
08/09/2017 8-K Quarterly results
03/01/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "Retrophin Reports Fourth Quarter and Full Year 2015 Financial Results",
"2016 Retrophin, Inc. Executive Officer Annual Bonus Plan"
11/03/2015 8-K Quarterly results
Docs: "Retrophin Reports Third Quarter 2015 Financial Results"
08/04/2015 8-K Quarterly results
Docs: "Retrophin Reports Second Quarter 2015 Financial Results"
05/12/2015 8-K Quarterly results
Docs: "Retrophin Reports First Quarter 2015 Financial Results"
08/12/2014 8-K Quarterly results
Docs: "Retrophin Reports Second Quarter 2014 Financial Results Management to Host Conference Call and Webcast today at 8:30 a.m. ET –"
05/14/2014 8-K Quarterly results
Docs: "Retrophin Reports First Quarter 2014 Financial Results Management to Host Conference Call and Webcast today at 8:30 a.m. ET –"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy